"Humans are the main reservoir of hVISA/VISA strains, which are capable of colonizing the environment and persisting, despite repeated and concerted eradication efforts."
The first hVISA strain was isolated in Japan in 1996 [3] . Since 1996, hVISA and VISA strains have increased in Europe, Asia and the USA, including over 100 cases [4] . VRSA strains are still rare, and the first case was documented in 2002.
As the VISA/VRSA isolates are also resistant to teicoplanin, the term glycopeptide-intermediate or glycopeptideresistant S. aureus is a technically more accurate term; however, the term VISA/VRSA is more widely used. In the USA, where teicoplanin is not available, the term VISA/VRSA is routinely applied [5] .
Patients most at risk of infection by hVISA, VISA and VRSA appear to be those with previous exposure to vancomycin. Treatment options for infections due to MRSA with reduced susceptibility to vancomycin are limited. Rapid and correct identification of patients harboring VISA, hVISA and VRSA, as well as the prompt infection-control protocols, are very important in controlling the dissemination and selection of these strains [1] .
Mechanism of resistance of hVISA/VISA
Strains of VISA have been observed to have lower growth rates and thicker cell walls than susceptible strains [4] . More murein monomers and more layers of peptidoglycan are considered to be present in the cell wall of VISA strains [3] .
Genetic ana lysis of VISA strains has provided further evidence that vancomycin resistance develops due to changes of several loss-of-function mutations affecting important cell wall biosynthesis and intermediary metabolism genes [6] .
The agr operon in S. aureus coordinates many critical virulence pathways. Activation of the agr operon induces the production of secreted virulence factors, such as hemolysins, exoproteins and exotoxins, and decreases the production of cell-associated virulence factors, such as adhesins. Expression of agr is inversely related to fibronectinbinding protein production, which offers selective advantage for the adherence to biomedical devices (e.g., catheters) and nasal colonization of patients or staff members. Under vancomycin exposure, loss of function of agr provides the selection of hVISA/VISA strains [7] .
As a result of the loss of agr function: Traditionally, the agar disk-diffusion test has been used to measure glycopeptide susceptibility, but this method is not suitable for large molecules, such as vancomycin, because the diffusion of this antibiotic into agar is too slow [8] .
An incorrect classification of MRSA as sensitive to glycopeptide antibiotics may occur, since glycopeptide MICs are dependent on test conditions. To date, no standardized technique for identifying hVISA strains has been established [4] .
A variety of different screening plates have been described. Some studies were screened with Mueller-Hinton agar instead of brain-heart infusion (BHI) agar. Others applied a different inoculum size (100 vs 10 µl), while others used different concentration of bacterial suspension (2.0 vs 0.5 McFarland). Several studies screened with plates containing vanomycin 6, 5 or 4 µg (or teicoplanin) per ml [4] . The sensitivity was varied between 58 and 98%, while the specificity was observed between 68 and 97%. The most suitable screening method seems to be the Mueller-Hinton agar plate containing teicoplanin 5 µg with 10 µl of 2.0 McFarland bacterial suspension incubated for 48 h [9] . "To date, no standardized technique for identifying hVISA strains has been established…" Acceptable methods used to detect VISA/hVISA are nonautomated. The most precise method of determination of heteroresistance is a population-ana lysis profile, as follows. After 24 h incubation in BHI, cultures were diluted in saline to 10 -3 and 10 -6 , and spiral plated on to BHI agar plates containing vancomycin 0.5, 1, 2, 2.5 and 4 mg/l. Colonies were counted after 48 h incubation at 37°C and the viable count was used to calculate an AUC. To distinguish VISA, hVISA and vanco mycin-sensitive S. aureus, a ratio of the AUC of test strains divided by the corresponding AUC for control strain was calculated. The criteria used for detection of hVISA and VISA were AUC ratios of at least 0.9 and at least 1.3, respectively [10] . The routine use of this method in a laboratory is time consuming and expensive; therefore, there is an urgent need for a simpler laboratory screening technique.
The macro E-test ® method may be one possible way to identify true hVISA strains under routine laboratory conditions. The strains are grown overnight to a 2.0 McFarland standard in Mueller-Hinton broth. A 200-µl sample is plated onto a BHI agar, and vancomycin and teicoplanin E-test ® strips are applied thereafter. Plates are incubated for 48 h and then evaluated for growth according to the CLSI. The newest available double-sided strip is the combined vancomycin and teicoplanin strip, known as the glycopeptide-resistance detection strip. This E-test is performed on Mueller-Hinton plates, rather then BHI. The inoculum is 0.5 McFarland and the incubation period is 48 h. The cut-off values after 48 h were teicoplanin of at least 12 mg/l, or both teicoplanin and vancomycin of at least 8 mg/l. The standard vancomycin MIC is at least 6 mg/l for VISA and at least 4 mg/l for hVISA. The specificity and the sensitivity of the glycopeptide-resistance detection test is 94 and 95%, respectively [9] .
Treatment of hVISA/VISA cases
The hVISA/VISA infections are usually associated with poorer patient outcomes. The mortality rate for hVISA/VISA patients is approximately 75% [6] .
Heterogeneous VISA seems to be the stage that precedes the development of VISA, therefore, when the vancomycin MIC is greater than 1 mg/l, alternative therapies should be considered to avoid the possibility of treatment failure and selection of hVISA/VISA strains.
Currently available drugs with activity against hVISA/VISA strains are linezolid, quinupristin/dalfopristin, trimethoprim/ sulfa methoxazole, the lipopeptide daptomycin and the tetracycline derivative tigecycline. Of these, trimethoprim/sulfamethoxazole and daptomycin are bactericidal. Trimethoprim/sulfamethoxazole is recommended in therapy only for skin and soft-tissue infections caused by hVISA/VISA strains. Experimental drugs with bactericidal activity against hVISA/VISA isolates include the lipoglycopeptide dalbavancin, the semisynthetic glyco peptide oritavancin, the glycolipodepsipeptide ramoplanin and a new broadspectrum cephalosporin, ceftobiprole. The in vitro activities of these drugs have been examined, although the clinical efficacy has not yet been established.
Currently, there are no formal recommendations regarding treatment of hVISA/VISA, and the future role of experimental and available antibiotics is unknown [6] .
Control of dissemination of hVISA/VISA strains
Humans are the main reservoir of hVISA/VISA strains, which are capable of colonizing the environment and persisting, despite repeated and concerted eradication efforts. Fundamental hygiene habits are the primary defense against dissemination of the bacteria, including wearing a gown on entry into the patient's room, use of an alcohol rub when washing hands on exiting the room, one-to-one nursing and routine contact investigation while the "Currently, there are no formal recommendations regarding treatment of hVISA/VISA, and the future role of experimental and available antibiotics is unknown."
